Eli Lilly's Mounjaro drug revenue surged 125% to $8.66 billion last quarter, prompting a raised full-year revenue forecast of $82-$85 billion and a market cap near $882 billion. Despite this, shares have already climbed significantly, making further gains challenging. Meanwhile, competitor Novo Nordisk faces sales declines and pricing pressures. Investors are now focusing on potential acquisitions upstream in biotech, with Viking Therapeutics, Scholar Rock, and Verve Therapeutics emerging as attractive targets due to their innovative therapies and strategic fits with Lilly and Novo. These smaller companies could be key to future growth in the competitive GLP-1 market.
Eli Lilly and Company announced its participation in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, the company's chief scientific and product officer, will engage in a fireside chat at 1:30 p.m. Eastern...
Novo Nordisk's oral weight-loss drug Wegovy continues to outperform Eli Lilly's Zepbound in the US market, with about 137,000 prescriptions in its 18th week, despite a 4% weekly decline. Citi notes that actual sales may be higher due to incomplete da...
Novo Nordisk is preparing to launch its Wegovy weight-loss pill outside the U.S. later this year, targeting major international markets like the UK, Germany, and Denmark. The company sees a significant opportunity to expand globally, leveraging teleh...
The healthcare sector, particularly healthcare equipment, is currently undervalued compared to historical averages. The iShares U.S. Pharmaceuticals ETF (IHE) has notably outperformed the broader healthcare ETF XLV by 27% over the past year, driven l...
Lance Roberts warns that the S&P 500 is significantly overextended above its key moving averages, increasing the likelihood of a mean-reversion correction of 10-15% this summer. Momentum indicators like the RSI and tech stock gauges support this over...
